ABVC - ABVC Biopharma rises fourfold amid social media buzz

ABVC Biopharma (NASDAQ:ABVC) has climbed more than ~400% in the pre-market in a move attributed to strong retail investor interest on the trading social network StockTwits. About 3.7M ABVC (ABVC) shares have changed hands, more than double the 65-day average of ~1.8M shares. The Fremont, California-based clinical-stage biopharma company is advancing therapeutics as well as medical devices in the fields of oncology/hematology, the central nervous system (CNS), and ophthalmology. The company currently has six drugs and a medical device called ABV-1701/Vitargus in its pipeline. In September, ABVC (ABVC) announced a joint venture (JV) agreement with Tokyo-based private investment firm Lucidam. In the same month, the company shares surged in reaction to the submission of two new patent applications for an active ingredient for its candidates targeting major depressive disorder (MDD) and attention-deficit Hyperactivity disorder (ADHD).

For further details see:

ABVC Biopharma rises fourfold amid social media buzz